ANTICONVULSANT DRUGS MARKET ANALYSIS

Anticonvulsant Drugs Market, by Drug Class (Barbiturates, Benzodiazepines, Aromatic allylic alcohols, Carboxamides, Triazine, AMPA receptor antagonists, Carbamate, Hydantoin, Fatty Acid Derivative, GABA analogs, Valproylamides, Others (Propionates, Oxazolidinediones, etc.)), by Route of Administration (Enteral, Parenteral), by Indication (Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Others (Borderline personality disorder, etc.)), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI2516
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Anticonvulsant Drugs Market - Key Players

Major players operating in the global anticonvulsant drugs market include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.

Anticonvulsant Drugs Market Report Snapshots